StockData

QuidelOrtho vs Qiagen

QDEL and QGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QDEL and QGEN compare

Qiagen grew revenue faster over the last twelve months (5.7% versus −4.5% for QuidelOrtho).

Qiagen keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −14.2% at QuidelOrtho.

Qiagen scores higher on the StockData Score (10 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQDELQGEN
Size and price
Market cap$677M–
Share price$9.87$49.75
Change, 1 year−53.7%6.6%
Change, 5 years−93.2%−16.3%
Beta (5Y)1.320.32
Employees6,5005,700
StockData Score
Total score610 (better)
Valuation score3 (better)0
Growth score02 (better)
Performance score24 (better)
Health score14 (better)
Dividend score00
Valuation
P/S0.3×–
P/B0.4×–
EV/EBITDA10.3×–
FCF yield−17.3%–
Fair value$26.64–
Margin of safety63.0%–
Growth
Revenue growth (TTM)−4.5%5.7% (better)
Revenue growth, 5Y average10.4% (better)2.2%
Net income growth (TTM)–408%
EPS growth (TTM)–424%
EPS growth, 5Y average–4.9%
Profitability
Gross margin44.2%62.2% (better)
Operating margin−4.9%22.3% (better)
Net margin−14.2%20.3% (better)
FCF margin−4.5%21.7% (better)
Return on equity−19.3%11.6% (better)
Return on invested capital−2.2%9.9% (better)
Financial health
Debt / equity1.640.44 (better)
Net debt / EBITDA8.290.84 (better)
Interest coverage−0.6×14.0× (better)
Current ratio1.363.90 (better)
Altman Z-score0.26–
Piotroski F-score68 (better)
Dividends and buybacks
Payout ratio–12.8%
Years of dividend growth–0
Buyback yield−0.66%–
Shareholder yield−0.66%–
Ownership
Held by institutions121%67.4%
Held by insiders43.4%0.00%
Insider net buying, 12 months$669K–
Short interest, % of float37.3%3.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.